Drugs / EQU-001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05004571 | Jul → Sep 2021 | — | Equilibre Biopharmaceuticals B.V. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05473442 | Dec 2022 → Jul 2023 | focal epilepsy | Equilibre Biopharmaceuticals B.V. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05063877 | Aug 2021 → Oct 2022 | epilepsy | Equilibre Biopharmaceuticals B.V. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EQU-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05473442 ↗ |
| Route | Oral | “will be given once orally to active-treatment subjects” NCT05004571 ↗ |